People's Daily - People's Daily Overseas Edition
Over the pile, slippery, 64-year-old Guo Guangyi skillfully do a variety of roller skating moves. It's hard to see that he was a cancer patient. In 2015, Guo Guangyi, who lives in Hohhot, Inner Mongolia, was diagnosed with rectal cancer and treated for nearly two years.
In 2017, Guo Guangyi, who was in a period of rehabilitation, walked in Dazhao Square in Hohhot, saw a group of elderly people participating in roller skating projects in the square, and made up his mind to practice roller skating. For 3 years, Guo Guangyi has practiced roller skating almost every day, and he has also joined difficult moves such as dancing fans and dragon dances.
The picture shows Guo Guangyi dancing fans while rollerblading in Dazhao Square on June 24.
Photo by Xinhua News Agency reporter Liu Lei
On April 16, Qiu Dong, deputy chief physician of the Department of Oncology of Guizhou Provincial People's Hospital, inspected patient imaging data. Photo by Xinhua News Agency reporter Ou Dongqu
On January 10, 2019, Yi Lili (left), a spiritual care specialist at Hunan Provincial Cancer Hospital, encouraged a cancer patient to write a mental diary to relieve stress. Photo by Xinhua News Agency reporter Xue Yuge
On May 29, China's panoramic dynamic PET-CT with independent intellectual property rights was put into use in Henan Provincial People's Hospital. This function can significantly improve the sensitivity and accuracy of tumor diagnosis. The picture shows a doctor in the nuclear medicine department of the hospital learning about this machine. Photo by Zhang Tao (People's Vision)
According to the data of China's tumor registration in the past five years, the incidence and mortality of malignant tumors in China are still on the rise. However, with the continuous improvement of medical level and medical quality, medical technology capabilities have continued to improve, and the 5-year survival rate of tumor patients has also steadily improved, and the quality of life has improved.
Continue to promote tumor quality control
Strengthen the standardized management of diagnosis and treatment
According to He Jie, director of the National Cancer Center, in recent years, the National Cancer Center and the National Cancer Quality Control Center have continued to promote tumor quality control and strengthen the standardized management of tumor diagnosis and treatment.
The first is to continuously improve the national, provincial and municipal tumor three-level quality control system, and 28 provinces have established provincial tumor-related quality control centers.
The second is to focus on strengthening the quality control and management of single tumor diseases. Single-disease quality control is an important method that has been proven by long-term practice to effectively improve the quality of medical care.
"The national tumor single disease quality control platform is under construction, and we will carry out tumor single disease quality control nationwide." Hejie said that the National Cancer Quality Control Center has carried out the pilot construction of standardized quality control of breast cancer diagnosis and treatment with breast cancer as a pilot, and at present, 200 hospitals above the third level have been included in the pilot scope, and the quality control of single diseases of lung cancer is also being tried.
The third is to continue to carry out the monitoring of the clinical application of anti-tumor drugs, and monitor the rational use of anti-tumor drugs in more than 1,400 medical institutions across the country, with the purpose of all-round management of diagnosis and treatment quality control and strengthening the standardized use of anti-tumor drugs.
The fourth is to continue to promote the construction of various forms of tumor medical associations and medical communities, carry out tumor telemedicine services, help the construction and development of grass-roots medical institutions, and enhance the ability of grass-roots tumor diagnosis and treatment.
More and more research results
Used to develop international standards
Hejie said that in the past 5 years, clinical research on tumors has been continuously carried out, and new technologies for diagnosis and treatment have been continuously promoted and applied. "With the improvement of China's clinical research level, more and more domestic cancer research results have been adopted by international authoritative tumor diagnosis and treatment standards setting institutions for the formulation of international clinical diagnosis and treatment standards, which has enhanced the international status of Clinical Research in China." At the same time, with the continuous development of tumor diagnosis and treatment technology, new technologies and new drugs have also been promoted and applied in the clinic. He said.
In terms of surgical treatment, China's new surgical methods, new concepts, and new research have made original breakthroughs. For example, thoracoscopic minimally invasive surgery and robot-assisted thoracic surgery have been gradually carried out, and the new concept of "anatomical partial lobectomy" originally developed by Chinese scholars has been accepted by the global thoracic surgery scientific community; tracing technology represented by fluorescently labeled lesions and lymph nodes, three-dimensional reconstruction and 3D printing preoperative simulation technology, nano-knife and other new technologies are gradually being widely used in clinical practice.
In terms of radiation therapy, the National Center for Oncology Quality Control has developed a number of radiotherapy quality control guidelines. There are 1413 radiation therapy centers in the country, about 86.2% of which can provide three-dimensional conformal radiation therapy, and about 67.4% of which can provide intensity-modulated radiation therapy, including four-dimensional CT or PET-CT simulation, image-guided radiation therapy and advanced technologies such as motion management.
In terms of drug therapy, new targeted drugs, immune drugs, and new treatment models are emerging, further improving the survival of cancer patients. For example, targeted drugs developed for many rare gene targets in lung adenocarcinoma have increased the benefit population to 70% ;PD-1 or PD-L1 monoclonal antibody-based combination therapy to reduce the risk of disease progression and death by 30%-40%; different forms of immunotherapy such as new vaccines and new generation immune dual antibodies have enabled some patients with advanced cancer to achieve remission and long-term survival.
In addition, a precision diagnosis and treatment system for targeted therapy and immunotherapy is gradually being established, and the selection of patients through markers can effectively improve the effectiveness of drug therapy. The noninvasive molecular typing system of peripheral blood established on this basis increased the number of patients benefiting from targeted therapy by 30%, and improved the accessibility of molecular typing.
In the next step, the National Cancer Center and the National Cancer Quality Control Center will continue to improve the management of tumor quality control, give full play to the role of the national tumor single disease quality control platform and the national anti-tumor drug clinical application monitoring network, carry out continuous monitoring of indicators related to the quality of tumor diagnosis and treatment in medical institutions, promote the continuous improvement of tumor diagnosis and treatment quality, and continuously improve the quality control system of tumor diagnosis and treatment in China.
Survival rates in patients with esophageal cancer
It is already higher than that of developed countries
Treating cancer and improving the level of cancer diagnosis and treatment is very important. In 2019, in the global medical quality and accessibility ranking published by Lancet magazine, China's medical level has risen to the top 50, making it one of the countries with the greatest improvement in medical level.
Hejie said that the process of cancer diagnosis and treatment in China is a process of rapid development, and new technologies, new drugs, and new diagnosis and treatment models are gradually recognized around the world, and are vigorously promoted and applied in the clinic. "The process of tumor diagnosis and treatment is a very complex process, and we have gradually developed from a single diagnosis and single treatment to precision diagnosis, precision treatment, and multidisciplinary joint diagnosis and treatment. At the same time, the Party Central Committee, the State Council and the National Health Commission attach great importance to it. Therefore, the level of tumor diagnosis and treatment in China has been greatly improved. He said.
According to reports, in terms of survival rate, the five-year survival rate of cancer patients in China has been significantly improved. From 30.9% a decade ago, it has risen to 40.5% today, an increase of nearly 10 percentage points. Taking breast cancer as an example, the improvement is even greater, and the five-year survival rate of breast cancer patients has reached 83%, which is similar to the level of diagnosis and treatment in developed countries. The five-year survival rate of patients with esophageal cancer is already higher than that of developed countries. All these show that the standardized diagnosis and treatment of tumors in China and the application of new surgical methods, new concepts and new research have obvious results.
In addition, China's high-level medical institutions, such as those in Beijing, Shanghai and Guangzhou, do not have a significant gap with developed countries in terms of survival rates of cancer patients.
"Of course, there is still a certain gap between the overall survival rate of cancer patients in China and developed countries, but under the leadership of the National Health Commission, we have further promoted the standardized diagnosis and treatment of tumors through the quality control and management of single tumor diseases and the monitoring of the clinical application of anti-tumor drugs, and gradually narrowed these gaps, and some even reached the international advanced level." Hett said.
Report shows global cancer cases to increase by 60% by 2040
The Cancer Atlas, compiled by the World Health Organization's International Center for Research on Cancer, the American Society for Cancer, the International Union for Cancer Control and others, shows that the number of global cancer cases will increase by 60% by 2040, according to current trends.
Smoking, infectious pathogens, overweight, etc. are the main carcinogenic risk factors. Among them, smoking is the number one risk factor, cancers associated with infectious pathogens account for about 15% of new cancer cases worldwide, and being overweight may increase the risk of developing 13 cancers.